Wed, Dec 4, 2024
[Archive]
Volume 2, Issue 3 (9-2012)
Iran J Ped Hematol Oncol 2012, 2(3): 103-108 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shahvazian N, Hashemi A, Farahzadi M, Sartipzade N. Combined Therapy with Deferiprone and Desferrioxamine as Compared to Desferasirox on Ventricular Function in Thalassemia Major Patients . Iran J Ped Hematol Oncol 2012; 2 (3) :103-108
URL: http://ijpho.ssu.ac.ir/article-1-79-en.html
URL: http://ijpho.ssu.ac.ir/article-1-79-en.html
Abstract: (9429 Views)
Abstract
Background
Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major. Combined therapy with deferiprone(DFP) and desferrioxamine (DFO)were suggested to be more effective than deferasirox(DFX) for removing heart iron. Deferasirox has recently been made available, but its long-term efficacy on cardiac function has not yet been established. Our study aimed to compare the effectiveness of deferiprone and desferrioxamine with deferasiroxon ventricular function in thalassemia major patients.
Materials and Methods
In this clinical trial study,72 thalassemia major (TM) patients were randomised to receive either deferiprone combined with desferrioxamine and deferasirox ,and thencardiac functions were evaluated. Data were analysed for left ventricular ejection fractions(LVEF)at baselinebyechocardiograpy, following 12 months of treatment.
Results
72 TM patientswere enrolled in this study lasting 12 months, 36 TMwere placed on DFP/DFO (DFP,50–86 mg/kg body weight DFO, 24–52 mg/kg body weigh), 36 received DFX (range 18–40 mg/kg body weight). In 36 patients receiving combined therapy, left ventricular ejection fraction increased from 59.3+/-5.7% to 63.7+/-5.1% (p=0.001) over 12 months [baseline LVEF values 56-61%]. Deferasirox showed no change in LVEF (p = 0.93).We found improvement of left ventricular ejection fractionsin the deferiprone combined with desferrioxamine versus the deferasirox group (P = 0.008).
Conclusion
The patients treated with combined therapy with deferiprone and desferrioxamine showed better systolic ventricular function compared to the patients treated with deferasirox. The patients treated with combined therapy with deferiprone and desferrioxamine showed better systolic ventricular function compared to the patients treated with deferasirox.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
